BioAge Labs Statistics
Total Valuation
BioAge Labs has a market cap or net worth of $825.03 million. The enterprise value is $524.20 million.
Important Dates
The next estimated earnings date is Friday, March 20, 2026, after market close.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAge Labs has 41.75 million shares outstanding. The number of shares has increased by 1,576.12% in one year.
| Current Share Class | 41.75M |
| Shares Outstanding | 41.75M |
| Shares Change (YoY) | +1,576.12% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.59% |
| Owned by Institutions (%) | 57.08% |
| Float | 34.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 137.39 |
| Forward PS | 135.13 |
| PB Ratio | 2.62 |
| P/TBV Ratio | 2.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 88.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.87, with a Debt / Equity ratio of 0.03.
| Current Ratio | 11.87 |
| Quick Ratio | 11.69 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -97.10 |
Financial Efficiency
Return on equity (ROE) is -25.64% and return on invested capital (ROIC) is -18.43%.
| Return on Equity (ROE) | -25.64% |
| Return on Assets (ROA) | -17.46% |
| Return on Invested Capital (ROIC) | -18.43% |
| Return on Capital Employed (ROCE) | -31.97% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $92,453 |
| Profits Per Employee | -$1.18M |
| Employee Count | 64 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +334.29% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +334.29% |
| 50-Day Moving Average | 18.89 |
| 200-Day Moving Average | 9.29 |
| Relative Strength Index (RSI) | 46.98 |
| Average Volume (20 Days) | 504,599 |
Short Selling Information
The latest short interest is 1.34 million, so 3.21% of the outstanding shares have been sold short.
| Short Interest | 1.34M |
| Short Previous Month | 909,129 |
| Short % of Shares Out | 3.21% |
| Short % of Float | 3.90% |
| Short Ratio (days to cover) | 1.55 |
Income Statement
In the last 12 months, BioAge Labs had revenue of $5.92 million and -$75.79 million in losses. Loss per share was -$2.11.
| Revenue | 5.92M |
| Gross Profit | -3.74M |
| Operating Income | -89.72M |
| Pretax Income | -75.79M |
| Net Income | -75.79M |
| EBITDA | -89.53M |
| EBIT | -89.72M |
| Loss Per Share | -$2.11 |
Full Income StatementBalance Sheet
The company has $285.78 million in cash and $7.13 million in debt, with a net cash position of $288.72 million or $6.92 per share.
| Cash & Cash Equivalents | 285.78M |
| Total Debt | 7.13M |
| Net Cash | 288.72M |
| Net Cash Per Share | $6.92 |
| Equity (Book Value) | 277.46M |
| Book Value Per Share | 7.74 |
| Working Capital | 266.34M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$58.51 million and capital expenditures -$633,000, giving a free cash flow of -$59.15 million.
| Operating Cash Flow | -58.51M |
| Capital Expenditures | -633,000 |
| Free Cash Flow | -59.15M |
| FCF Per Share | -$1.42 |
Full Cash Flow StatementMargins
| Gross Margin | -63.17% |
| Operating Margin | -1,516.29% |
| Pretax Margin | -1,280.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAge Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,576.12% |
| Shareholder Yield | -1,576.12% |
| Earnings Yield | -9.32% |
| FCF Yield | -7.28% |
Analyst Forecast
The average price target for BioAge Labs is $44.40, which is 124.70% higher than the current price. The consensus rating is "Buy".
| Price Target | $44.40 |
| Price Target Difference | 124.70% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioAge Labs has an Altman Z-Score of 4.7 and a Piotroski F-Score of 1.
| Altman Z-Score | 4.7 |
| Piotroski F-Score | 1 |
